Net open-market buying, 180d$5.0M · 94 pct, sector of 442
Insider buyers, 180d2 · 79 pct, sector of 449
Risk and compliance
63
Inputs
Short interest, % of float+3.8% · 63 pct, sector of 814
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Institutional and government, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
What the filings say about LTGO
In the 180 days to 2026-10-12, Latigo Biotherapeutics insiders were net buyers of LTGO, a net $5.0M across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $5.0M, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 14.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.
LTGO filings FAQ
Are Latigo Biotherapeutics insiders buying or selling LTGO?
In the 180 days to 2026-10-12, Latigo Biotherapeutics insiders were net buyers, a net $5.0M across purchases and sales reported on Form 4, by 2 buyers.
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Latigo Biotherapeutics, Inc. insiders bought a net $5.0M of stock across 2 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-10-12.
First open-market trade here by this insider on our record.
The trade is 7.0% of the 2,008,024 shares held after it.
1 other insider bought within 30 days.
Insider activity: Director Tananbaum James B. bought about $2.5M of LTGO on the open market on Aug 10, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
First open-market trade here by this insider on our record.
The trade is 7.0% of the 2,008,024 shares held after it.
1 other insider bought within 30 days.
Insider activity: Insider Foresite Capital Management V, LLC bought about $2.5M of LTGO on the open market on Aug 10, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
No password to create and no card required. We store your email address and nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in. Google Analytics and
Microsoft Clarity load only if you allow them here, to show us which datasets matter.
No ad trackers, ever. Details in the privacy
policy.
